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Age-related macular degeneration (AMD) is the leading cause of vision loss in those over the age of 50
years in the developed countries. The number is expected to increase byw1.5 fold over the next ten years
due to an increase in aging population. One of the main measures of AMD severity is the analysis of
drusen, pigmentary abnormalities, geographic atrophy (GA) and choroidal neovascularization (CNV) from
imaging based on color fundus photograph, optical coherence tomography (OCT) and other imaging
modalities. Each of these imaging modalities has strengths and weaknesses for extracting individual
AMD pathology and different imaging techniques are used in combination for capturing and/or quan-
tiﬁcation of different pathologies. Current dry AMD treatments cannot cure or reverse vision loss.
However, the Age-Related Eye Disease Study (AREDS) showed that speciﬁc anti-oxidant vitamin sup-
plementation reduces the risk of progression from intermediate stages (deﬁned as the presence of either
many medium-sized drusen or one or more large drusen) to late AMD which allows for preventative
strategies in properly identiﬁed patients. Thus identiﬁcation of people with early stage AMD is important
to design and implement preventative strategies for late AMD, and determine their cost-effectiveness. A
mass screening facility with teleophthalmology or telemedicine in combination with computer-aided
analysis for large rural-based communities may identify more individuals suitable for early stage AMD
prevention.
In this review, we discuss different imaging modalities that are currently being considered or used for
screening AMD. In addition, we look into various automated and semi-automated computer-aided
grading systems and related retinal image analysis techniques for drusen, geographic atrophy and
choroidal neovascularization detection and/or quantiﬁcation for measurement of AMD severity using
these imaging modalities. We also review the existing telemedicine studies which include diagnosis and
management of AMD, and how automated disease grading could beneﬁt telemedicine. As there is no
treatment for dry AMD and only early intervention can prevent the late AMD, we emphasize mass
screening through a telemedicine platform to enable early detection of AMD. We also provide a
comparative study between the imaging modalities and identify potential study areas for further
improvement and future research direction in automated AMD grading and screening.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-
y medium, provided the original author and source are credited.
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Age-related macular degeneration (AMD) is the leading cause of
vision loss in those over 50 years old in the industrialized world.
Currently, approximately 35% of adults older than 80 in the United
States, for example, are estimated to have intermediate or advanced
AMD (National-Eye-Institute, 2004). The number of people with
this condition is expected to increase w1.5 fold over the next ten
years due to an aging population, and a higher prevalence of
vascular risk factors such as hypertension contributing (Bartlett and
Eperjesi, 2007). AMD can be broadly divided into early, interme-
diate and late stage AMD. Early and intermediate AMD, sometimes
called early “dry” AMD, is associated with drusen and pigmentary
changes in the retina and is associated with only minimal visual
symptoms. Late AMD has two subtypes, a progressive geographic
atrophy in the macula region, sometimes called late “dry” AMD; or
exudative AMD due to the development of choroidal neo-
vascularization, sometimes called “wet” AMD. While treatment of
exudative AMD with anti-vascular endothelial growth factor (anti-
VEGF) agents has been revolutionary and is effective in maintaining
vision, such treatments are costly and may be associated with
signiﬁcant cardiovascular risks (Wong, 2009). Furthermore,
although these treatments may be effective for the exudative or
neovascular component of AMD, they have not been shown to be
able to stop or reverse the atrophic processes of dry AMD (Lim et al.,
2012; Meleth et al., 2011; Schmitz-Valckenberg et al, 2009). The
Age-Related Eye Disease Study (AREDS) showed that speciﬁc anti-
oxidant vitamin supplementation (AREDS formulation) reduces
the risk of progression from intermediate stages (deﬁned as the
presence of either manymedium-sized drusen or one ormore large
drusen) to late AMD, that can allow for preventative strategies
(Age-Related Eye Disease Study Research Group, 2007). Thus, early
identiﬁcation of people with selected AMD is important, as it en-
ables implementation of disease prevention strategies. For
example, approximately 7.6% of the United States population over
the age of 60 are estimated to have advanced or intermediate AMD,
amenable to such treatment (National-Eye-Institute, 2004). Recent
publications looking at the ten-year experience of appropriately
selected patients taking AREDS formulation demonstrates that it is
effective at slowing disease and improving visual acuity in
approximately 25% of patients (Chew et al., 2013).
The classic method of early and intermediate stage AMD detec-
tion is retinal color photography to detect drusen (i.e., deposits of
lipids and other metabolic products that form beneath the retinal
pigment epithelium (RPE), (Rapantzikos et al., 2003) in the macula
area. Furthermore, area quantiﬁcation and classiﬁcation of drusen in
these color images can be accomplished through image analysis
(Smith et al., 2003, 2005) (Abramoff et al., 2010). Other imaging
techniques are also used in AMD detection and screening. These
include non-invasive imaging techniques such as optical coherencetomography (OCT), fundus autoﬂuorescence (FAF), and infrared (IR)
imaging. More invasive techniques such as ﬂuorescein angiography
(FA) and indocyanine green (ICG) angiography, that require dye in-
jection, are used to delineatethe AMD clinical statusmore accurately.
In this review, we focus our discussion on existing methods for
detecting AMD lesions, e.g., drusen, geographic atrophy (GA) and
choroidal neovascularization (CNV), from these retinal imaging
modalities. The review also analyses current retinal imaging tech-
niques and their relative strengths and weaknesses for detecting
and classifying AMD pathologies. Topics discussed include:
 current image analysis techniques, exploring strengths and
areas for further improvement
 review of existing AMD grading protocols and identiﬁcation of
the requirements of automation for mass screening based on
AMD protocols
 review of telemedicine-based systems for AMD screening
 comparison and contrast of each of the imaging modalities and
their scientiﬁc merits for any particular AMD pathology
detection
 delineating future research directions for early AMD detection
through mass screening of large populations.1.1. Method of literature search
We performed a comprehensive literature review on AMD im-
agingmodalities and telemedicine for the diagnosis and screening of
AMD.Acomputerized searchof the PubMeddatabase and theWebof
Science database was performed to identify all pertinent peer-
reviewed articles published up till mid April 2013. The keywords
used for the search included age related macular degeneration, im-
aging techniques, screening, diagnosis, imaging modalities, macula,
drusen, geographic atrophy, choroidal neovascularisation, dry AMD,
wet AMD, color fundus photograph, fundus autoﬂuorescence, angi-
ography, optical coherence tomography, spectral domain optical
coherence tomography, indocyanine angiography, hyperspectral imag-
ing, infrared imaging, telemedicine, and clinical trials.1.2. Criteria of inclusion
All abstracts were examined to identify if articles were imaging
or telemedicine, and related to the quantiﬁcation of AMD pathol-
ogies, AMD screening or diagnosis.1.3. Criteria of exclusion
Papers and abstracts were excluded from review if they were
not peer-reviewed. AMD pathology segmentation papers which did
Fig. 1. Retinal colour image showing many drusen in the macula (left) and geographic atrophy (right).
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excluded from consideration.
1.4. Selection of papers
Once the inclusion and exclusion criteria were examined, copies
of the entire articles were obtained and citations were entered into
Endnote. In the ﬁnal stage, articles were reviewed and information
relating to quantiﬁcation of AMD pathologies or AMD screening
was included in this review.
The remainder of this review article is organized as follows: A
brief description of AMD stages and existing diagnosis techniques
for AMD is provided in section two. Section three provides a brief
description and summary of image analysis techniques for AMD
pathology detection and quantiﬁcation. A comparative study of
different AMD imaging modalities is provided in section four. A
brief overview of existing AMD telemedicine platforms for
screening is provided in section ﬁve. In section six, a brief
description is provided of existing clinical trials for the identiﬁca-
tion and follow-up of AMD patients. In section seven, the limita-
tions of current imaging modalities are stated. Finally, conclusions
and future research directions are drawn in section eight.
2. Classiﬁcation and diagnostic and screening techniques for
AMD
2.1. Classiﬁcation of AMD
The early stages of AMD include soft drusen and reticular
pseudodrusen, aka reticular macular disease.
2.1.1. Hard drusen and soft drusen
Drusen are the classic initial lesions of early, dry AMD. Drusen
can be deﬁned as hard and soft. Hard drusen are small lesions with
sharp borders (Fig. 1 left) and soft drusen are those with indistinct
borders (Fig. 1 left). Most studies agree that hard drusen alone carry
no adverse prognostic signiﬁcance. Soft drusen, however, have long
been recognized as precursors to advanced AMD (Bressler et al.,
1988). They are pale yellow deposits of cholesterol and other ma-
terials beneath the RPE, sometimes also associated with pigment
clumps.
2.1.2. Reticular pseudodrusen (RPD) aka reticular macular disease
(RMD)
These lesions, although described earlier, are now attracting
widespread attention because of their visibility in advanced im-
aging modalities and their strong association with advanced AMD.
Mimoun et al. (1990) described them as a peculiar yellowish
pattern of “pseudodrusen visible in blue light,” because of their
enhanced visibility using blue light fundus photography. In 1991,Klein et al. called them “reticular soft drusen” in the Wisconsin
Age-Related Maculopathy Grading System. The ﬁrst reference to
“reticular pseudodrusen” was made by Arnold et al. (1995)
With the advent of autoﬂuorescence (AF) imaging, Smith et al.,
2006 made the connection between reticular pseudodrusen on
fundus photography and a reticular pattern on AF imaging.
Upon further investigation with Scanning Laser Ophthalmology
(SLO) imaging, including near infrared reﬂectance (NIR-R) and
indocyanine green angiography (ICG), Smith et al. (2009), proposed
“reticular macular disease” as a distinct phenotypic entity in the
classiﬁcation of AMD, with reticular pseudodrusen being a clinical
feature of reticular macular disease. Analyzing these lesions with
spectral domain optical coherence tomography (SD-OCT), Zweifel
et al. (2010) found that they are localized between the RPE and
the inner segment/outer segment boundary (now referred to as the
“inner segment ellipsoid (ISe) band”) and referred to reticular le-
sions as “subretinal drusenoid deposits” (SDD). RPD are a risk factor
for advanced AMD and their detection should be part of the
ophthalmologic screening examination for AMD. Dry atrophic
AMD, or geographic atrophy (GA) occurs when there is combined
loss of photoreceptors, RPE and choriocapillaris over a well-deﬁned
area or areas (multilobular form). If this process affects the fovea,
there can be severe central visual loss.
2.1.3. Early “dry” AMD
In the early and intermediate stages of AMD, the transport of
nutrients and wastes by the RPE slows down and waste accumu-
lates under the RPE forming yellowish deposits called drusen (Fig. 1
Left) (Rapantzikos et al., 2003; Bartlett and Eperjesi, 2007). As the
RPE continues to slow down in its transport of nutrients and
wastes, the overlying photoreceptors become damaged, up to legal
blindness.
Late “dry” AMD or GA occurs with progressive atrophy of the
RPE, choriocapillaris and photoreceptors (Lim et al., 2012)(Fig.1
right). It is characterized by sharply delineated areas of severe
depigmentation or apparent absence of the RPE, through which
larger choroidal vessels are more easily seen, with a minimum
diameter of 175 mm (Baumann et al., 2010). Late “dry” AMD ac-
counts for 80e90% of all diagnosed patients. Progression tends to
be slow, and is measured over years. The fovea can be spared until
late in the disease.
“Wet” AMD or neovascular AMD, refers to the proliferation of
new vessels either under the RPE, breaking through the RPE, or
within the neural retina, leading to death of the photoreceptors
from exudative damage (ﬂuid, lipids and blood, ultimately leading
to ﬁbrous scarring). The ﬁrst two forms are types of choroidal
neovascularization (CNV), whereas the third, known as retinal
angiomatous proliferation (RAP), begins as intraretinal neo-
vascularization. As a result, objects in that portion of the visual ﬁeld
may appear wavy or distorted, known clinically as metamorphopsia
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untreated, resulting in permanent legal blindness.
The physiology of the aging macula and current understanding
of the mechanisms implicated in the causes of AMD can be
reviewed (Bressler et al., 1988; Ryan et al., 2013). Clinical and his-
topathological features of AMD, as well as related genetics and
epidemiology, can be found in the review by Jager et al. (2008).
However, it must be recognized that all of these topics are under
active research, with new data and proposed disease paradigms
appearing frequently. The natural history of AMD has been fairly
well documented (Wong, 2009.2.2. Diagnostic tests for AMD
The tests below are widely used in eye clinics for AMD
diagnosis:
 Visual acuity
 Amsler grid test
 Slit lamp biomicroscopy examination
 Color fundus photography.
Details on these diagnostic approaches can be found in the re-
view of Freund (Freund et al., 2008). These tests may be most
appropriately utilized as initial tests for AMD.
The following imaging modalities can subsequently be used for
further analysis:
 Fundus Autoﬂuorescence (FAF) Imaging
 Optical Coherence Tomography (OCT)
 Fluorescein Angiography (FA)
 Indocyanine Green (ICG) Angiography
 Thermal or Infrared (IR) Imaging
 Hyperspectral Retinal Imaging (HRI).2.3. Diagnostic imaging modalities
In this section we brieﬂy introduce different imaging modalities
that are used for AMD screening and follow up diagnostic tests.
2.3.1. Imaging modalities for AMD screening
Color fundus photography (ﬁlm initially but more recently
digital) has been the gold standard for AMD screening and is a rapid
way to look for soft drusen, the earliest sign of AMD (Kösea et al.,
2008; Sbeh et al., 2001). Fundus cameras, however, are expensi-
ve.FAFis another imaging modality which may be used to screen
early AMD (Framme et al., 2005). FAF is also an excellent way to
visualize reticular macular disease (Xu et al., 2013).Fig. 2. An autoﬂuorescence image of the retina with dry macular degenerat2.3.1.1. Fundus photography for AMD screening. A digital fundus
camera is used to capture an image of the interior of the eye,
including the retina, optic disc, and macula (Fig. 1). A specialized
low powermicroscope with an attached digital camera is designed
for color fundus photography and uses visible spectrum light for
imaging the retinal structure in vivo. In color imaging, the image
intensities represent the amount of reﬂected red, green and blue
wavelengths, as determined by the spectral sensitivity of the
sensor. Since the level of ambient light normally striking the retina
creates insufﬁcient reﬂected illumination for digital imaging,
external illumination must be projected into the eye, and the light
reﬂected by the retina must re-traverse the pupillary plane. As a
result, separate paths must be used in the pupillary plane, resulting
in optical apertures of the order of a few millimeters to avoid
overlap between corneal and lenticular reﬂections (Abramoff et al.,
2010).
2.3.1.2. Fundus Autoﬂuorescence (FAF) for AMD screening. FAF im-
aging may allow for identiﬁcation of retinal diseases when these
are not otherwise evident through color imaging. It is an in vivo
imaging method for metabolic mapping of naturally or pathologi-
cally occurring ﬂuorophores of the ocular fundus (Fig. 2). Metabolic
changes at the level of the photoreceptor/RPE complex are not
visualized by digital fundus image or other routine imaging tech-
niques such as FA in the early manifestations of macular and retinal
dystrophies (Fleckenstein et al., 2010a,b). FAF may be particularly
helpful to investigate patients with unknown visual loss or with a
family history of hereditary retinal diseases.
In FAF, the dominant sources appear to be ﬂuorophores such as
A2-E in lipofuscin granules that accumulate in the postmitotic RPE
as a by-product of the incomplete degradation of photoreceptor
outer segments. However, the dominance of A2-E in themacula has
recently been disproved by imaging mass spectroscopy (Ablonczy
et al., 2013), so additional research is needed to identify these
compounds accurately. Additional intrinsic ﬂuorophores may occur
with disease in the various retinal layers or the subneurosensory
space. Minor ﬂuorophores such ascollagen and elastin in choroidal
blood vessel walls may become visible in the absence or atrophy of
RPE cells (Fleckenstein et al., 2010a,b). There are two noninvasive
ways to obtain these images; one uses a specialized scanning laser
ophthalmoscope, and the other uses special ﬁlters attached to the
fundus camera.
2.3.2. Imaging modalities for diagnosis of early or late “dry” AMD
Drusen (early “dry” AMD) and GA (late “dry” AMD) are identi-
ﬁed by imaging modalities such as color fundus photography, FAF
and spectral domain optical coherence tomography (SD-OCT). Until
the advent of SD-OCT, color fundus and FAF most reliably assessed
drusen and GA, respectively. With SD-OCT, small and medium-size
drusen may be more clearly seen as discreet areas of RPE elevationion (left) and more advanced form of dry macular degeneration (right).
Fig. 3. An OCT device (top-left) and OCT image for normal and wet AMD (top-right). Gray scale image showing the line for OCT B scan (bottom left side) and an OCT scan showing
depth of the line.
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underlying material (Fig. 3). With larger drusen or drusenoid
pigment epithelium detachment (PED), greater elevation of RPE
may be seen, often dome shaped, with a hypo or medium reﬂective
material separating the RPE from the underlying Bruch’s mem-
brane (Keane et al., 2012).
2.3.2.1. Fundus photography of early or late “dry” AMD. Color digital
fundus photography has been used to grade and quantify soft
drusen and GA (Smith et al., 2003; Scholl et al, 2003) as part of GA
diagnosis. Most of the existing methods for evaluating color
fundus-based drusen and GA grading are manual and semi-
automatic. This may be because drusen subtypes such as soft
distinct and soft indistinct drusen are very difﬁcult to measure
within their irregular and blurred boundaries. Fig. 1 shows soft
drusen in a color fundus image.
2.3.2.2. Fundus Autoﬂuorescence (FAF) of early or late “dry” AMD.
FAF imaging is mainly used to quantify GA for late “dry” AMD
diagnosis. FAF gives information above and beyond that obtained
by conventional imaging methods such as digital fundus photog-
raphy. GA represents the loss of RPE, and it manifests as a markedly
reduced FAF signal (Schmitz-Valckenberg et al, 2008).
2.3.2.3. Spectral Domain Optical Coherence Tomography (SD-OCT) of
early or late “dry” AMD. SD-OCT is widely used for both late “dry”
and “wet” AMD diagnosis, as it is well capable of capturing the area
and volume of the AMD pathologies. It is one of the most recent
noninvasive technologies developed for recording the features of
the retina, and it displays the information as cross-sectional views,
or optical slices, i.e., mapping the layered anatomy of the retina
(Fig. 3). SD-OCT functions as a type of optical biopsy, providing
information on retinal pathology in real time, with a resolution
vastly better than magnetic resonance imaging (MRI) or ultra-
sound. Amajor strength of SD-OCTover other imaging modalities is
its ability to capture 3D-volumetric information about the pathol-
ogies. It has therefore been widely used in advanced AMD
diagnosis.The principle of OCT is the estimation of the depth at which a
speciﬁc backscatter originated by measuring its time of ﬂight.
Backscatters are typically caused by differences in refractive index
in transitions from one tissue to another. Backscatter from deeper
tissues can be differentiated from backscatter originating at more
superﬁcial tissues because it takes longer for light to arrive at the
sensor from deeper tissues. With a total retinal thickness between
300 and 500 mm, the differences in time of light relay are very small
and are measured through interferometry, which OCT utilizes
(Abramoff et al., 2010). The OCT imaging procedure is convenient
and rapid for the patient. Huang et al. (Huang et al., 1991) describes
the early OCT imaging technique, which aimed to capture 2D im-
ages. Commercially available OCT allows collection of up to 400 A-
scans per second, which is not suitable for 3D imaging (Abramoff
et al., 2010). In the original OCT imaging technique, very weak
laser light is used to map the anatomy of the retina as the reﬂected
image returns to a series of mirrors, with resulting reconstruction
of computer processed images (Fig. 3) which are saved for analysis
(Freund et al., 2008).
With SD-OCT, up to 40,000 A-scans can be acquired per sec-
ond, which is enough for 3D imaging (Schimel et al, 2011). In SD-
OCT the source beam is split in a similar fashion to time domain
OCT (TD-OCT), but no moving mirror is required in data capture. A
spectrometer is employed to analyze light frequency changes that
occur from reference and subject beam interaction (Schimel et al,
2011). The Fourier transform is applied to the spectral correlo-
gram intensities to determine the depth of each scatter signal
(Abramoff et al., 2010). Spectral domain (SD) or Fourier domain
allows the instrument to scan the retina much faster, providing
very high-resolution 3-D images of the retina. SD-OCT is better
than time domain OCT (TD-OCT) for pathology quantiﬁcation (Yi
et al., 2009) in accuracy, area and volume measurement, noise
handling and speed, and it has become the standard of care for
AMD.
SD-OCT is an excellent modality to visualize subretinal druse-
noid deposits (SDD) (Zweifel et al., 2010).
A brief summary of existing commercially available SD-OCT
devices is given in Kiernan et al. (2010). With SD-OCT, the
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tissue layers and relationships among layers. SD-OCTalso allows for
repeated examination of the exact same areas of the retina for each
patient visit, resulting in more precise measurement of the effects
of treatment.
2.3.3. Imaging modalities for diagnosis of exudative AMD
Exudative or “wet” AMD represents CNV, predominantly diag-
nosed with SD-OCT or ﬂuorescein angiography in current practice.
2.3.3.1. Spectral Domain Optical Coherence Tomography (SD-OCT) of
exudative AMD. SD-OCT imaging is highly suited to image the ﬂuid
associated with CNV, displaying characteristic as well as atypical
images of neovascularization at the level of RPE and subretinal
space. Other neovascular conditions that may be delineated with
SD-OCT include polypoidal choroidal vasculopathy and peripapil-
lary and peripheral CNV (Keane et al., 2012). Fig. 3 shows the ﬂuid
accumulation due to CNV in an SD-OCT scan of a patient with
exudative AMD. OCT evaluations have greatly augmented but not
entirely replaced angiography. OCT provides different information
to angiography, such as whether excess ﬂuid is present in the
retina, as opposed to the site of a leak. OCT is extensively used for
monitoring the progress of treatment for “wet” macular degener-
ation. Additional common clinical applications of SD-OCT related to
CNV are to initiate diagnosis and therapy, to determine the ongoing
effect of anti-angiogenic treatment and to guide the termination of
anti-angiogenic therapy (Keane et al., 2012). Caution must be used
in interpretation of ﬂuid ﬁlled spaces seen on SD-OCT. The presence
of ﬂuid does not necessarily imply that CNV is active. Fluid may be
present in inactive degenerative cysts, or in outer retinal tabulation,
a common feature of retinal degenerations including AMD. Clinical
judgment is warranted to avoid unnecessary treatment.
2.3.3.2. Fluorescein Angiography (FA) of exudative AMD.
Angiography, both ﬂuorescein and indocyanine green (ICG), is
another useful test to look for CNV. A small gage needle attached to
a plastic catheter is inserted into a vein, usually in the arm, and aFig. 4. Standard OCT scans showing choroidal vasculature: (a) OCT volume with segment
membrane. (c) Sub-volume under Bruch’s membrane containing the entire choroid. (d) Or
(green line) ﬁtting around the choroidal vasculature, used to determine choroidal vasculatu
choroidal vessels (image taken from (Abramoff et al., 2010)).ﬂuorescent dye is injected through the catheter and enters the
bloodstream. As the dye enters the blood vessels of the eye, a series
of pictures are taken of the retina using a fundus camera. Special
ﬁlters matched for the excitation and emission wavelengths of the
dye are placed in a beam splitter so that only the ﬂuorescence of the
dye in the blood vessels is visualized against the dark remainder of
the background retinal tissue (Fig. 5). By looking at the pattern of
the blood vessels and observing whether dye leaks from any ves-
sels, an ophthalmologist can locate sites of CNV if they are present
(Fig. 5, right).
Sometimes, an area of CNV is not clearly deﬁned, or it may be
obscured by overlying ﬂuid or blood. In these cases ICG dye is used
instead of ﬂuorescein (Fig. 6), as discussed in the next subsection.
Fig. 4.
2.3.4. Other imaging modalities
2.3.4.1. Indocyanine Green (ICG) angiography. ICG is also useful for
visualizing the deeper blood vessels located in the choroid. ICG can
demonstrate how the choroidal circulation interacts with other
layers of the retina and whether variant forms of CNV, such as
retinal angiomatous proliferation (RAP) or polypoidal choroidal
vasculopathy are present (Freund et al., 2008). ICG has been useful
for detecting CNV in neovascular AMD (Chang et al., 2004).
ICG is a cyanine dye and absorbs light in the near-IR range of
790 nme805 nm and ﬂuoresces in the IR (non-visible) range.
These long wavelengths allow for visualization of the dye through
overlying melanin and xanthophyll. The IR wavelengths also have
the ability to penetrate the retinal layers making circulation in
deeper layers (e.g., choroid) visible (Fig. 6). The detection proce-
dure is similar to ﬂuorescein angiography, but utilizes a dye and
detection ﬁlters that allow capture in the IR (non-visible) light
range.
2.3.4.2. Thermal/Infrared (IR) imaging. IR imaging provides a non-
invasive, in vivo method to image early changes in the RPE/Bruch
membrane. It offers advantages over current imaging techniques by
minimizing light scattering through cloudy media. It also enhancesed Bruch’s membrane (blue line). (b) Flattened OCT volume with segmented Bruch’s
iginal OCT volume with superimposed segmented vessels (pink outlines) and surfaces
re thickness and choriocapillaris-equivalent thickness. Red arrow points to one of the
Fig. 5. Fundus camera and angiography images (left) and ﬂuorescein angiogram shows
CNV in the macula (right). ICG angiogram shows a bright area of CNV in the macula.
The CNV was not visible with ﬂuorescein dye because of abnormal ﬂuid beneath the
retina.
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tion, blood, heavy lipid exudation, or subretinal ﬂuid. It provides
additional information regarding early CNV, and the character of
drusen and sub-retinal deposits (Hartnett and Elsner, 1996).Fig. 6. Red-free photograph of a patient with classic choroidal neovascularization (CNV)In IR imaging with an SLO, light in the 820 nm wavelength is
used to illuminate the tissue. During scanning, reﬂections from the
tissue are acquired. IR imaging detects pathology despite the
presence of hemorrhage or cataracts, that may be undetected in
other in vivo studies such as angiographic dye (Schardosim et al,
2011). The Heidelberg retina angiograph2 (HRA2) has an IR scan
mode. Fig. 7 shows IR retinal images (Kolar et al., 2008) for CNV.
However, IR is not considered diagnostic for CNV, because these
images cannot deﬁne leakage or intraretinal ﬂuid, but only show a
suggestive subretinal ﬁbrotic ring.
A limitationwith using a digital fundus camera to provide useful
IR images can be attributed to its failure to separate reﬂected and
scattered light, since IR light is absorbed less than visible light and
thus may scatter over longer distances. Consequently, IR fundus
images are often noisy and present low detail deﬁnition. IR fundus
images of static scenes taken at different time instants (i.e., infrared
image sequences), tend to present pixel value ﬂuctuations in time
(Schardosim et al, 2011). This defect is largely overcome by use of a
confocal SLO such as the HRA2 or Spectralis that rejects light
scattered outside the plane of focus.
2.3.4.3. Hyperspectral Retinal Imaging. Hyperspectral retinal im-
aging (HRI) is a new imaging technique which is capable of
providing both spatial and spectral retinal information and con-
structing a 3D data cube for multivariate data analysis (Diaconu,
2009). It is well suited for detecting AMD pathology, such as dru-
sen. Hyperspectral imagers commonly employ one of two methods
to separate light into spectral components: dispersive optics (for
example, a prism) and interferometers. In a dispersive spectrom-
eter, light passes through the entrance slit and is collimated by a
lens before it hits the wavelength selection device, typically a prism
or grating which separates the light into its spectral components
(Davis et al., 2007). Hyperspectral analysis has been applied to
drusen as well as macular pigment and retinal oximetry. There is
signiﬁcant untapped potential for optical molecular biopsy of living
tissue with this method (Lee et al., 2010; Fawzi et al., 2011; Gao
et al., 2012).3. Image analysis techniques for AMD
The imaging-based diagnostic techniques for AMD focus on
detecting different pathologies through variations of retinal imag-
ing. Each of the imaging modalities has strengths and limitations in
capturing individual pathology. In this section, we focus on the
imaging modalities and different automated and semi-automated
techniques that are used to quantify the pathologies.(left) and early-phase ICG angiogram reveals hyperﬂuorescence of the CNV (right).
Fig. 7. Infrared frames of well-deﬁned choroidal neovascularisation. This composite frames show nine examples of eyes affected with well-deﬁned choroidal neovascularisations
(CNVs) in exudative AMD. In infrared pictures, the well-deﬁned CNV appear as a complex with a dark central core surrounded by a whitish reﬂective ring, giving a halo-like shape
(black arrows). This whitish ring may have an O-shape (A, C, E, F, H) or a horseshoe aspect (U-shape) (B, D, G, I) (Semoun et al., 2009).
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Existing algorithms for early and late “dry” AMD screening using
color fundus image analysis mainly focus on the detection and
quantiﬁcation of drusen, with a few methods discussed for GA
quantiﬁcation. These automatic or semiautomatic image analysis
methods include image normalization and enhancement, macular
area mapping, and segmentation of drusen and GA. Image
normalization is usually essential as the irregular shape of the
retina creates shading across the ﬁeld of view when illuminated by
a bright ﬂash in the fundus camera. Contrast appearance tech-
niques have been used to improve the appearance of details in the
retinal image before processing. In this discussion we categorize
techniques based on the main image analysis steps such as texture,
edge, mathematical morphology, intensity thresholding and
clustering-based segmentation techniques.
3.1.1. Color fundus imaging for “dry” AMD
3.1.1.1. Texture-based drusen segmentation. Texture generally de-
scribes the property of surfaces and scenes, measured over image
intensities. Drusen, which are brighter in the retinal surface, have a
different response than the background if the appropriate texture
methods are applied. Using this hypothesis, a number of methods
have been proposed which are based on Gabor ﬁlter and wavelet
analysis (Kose et al., 2010), (Parvathi and Devi, 2007), (Lee et al.,
2008). In Gabor ﬁltering an input image Iðx; yÞ; ðx; yÞ˛U, where U
is the set of image points, is convolvedwith a 2D Gabor function g(x,
y), ðx; yÞ˛u to obtain a Gabor feature image r(x, y) (Kruizinga andPetkov, 1999). These functions are used to extract texture infor-
mation that mainly reﬂects a variation in response along different
orientations on different surfaces. For example, the response for
texture of drusen areas and background texture are different with
respect to their color and intensity distributions.
The wavelet transformation is also used to achieve better results
than the Fourier transformation, as wavelets have advantages of
spatial localization and basis function ﬂexibility (Brandon and
Hoover, 2003). A number of basis functions for the orthonormal
wavelet transform were used, which were similar in shape to a
typical drusen. A combination of amplitude modulation (AM) and
frequency modulation (FM) has been used to generate multi-scale
features for classifying pathological structures, i.e., drusen. The
AM-FM is applied on different scales to represent an input digital
image as the sum of AM-FM components (Barriga et al., 2009). The
AM functions characterize slowly-varying image intensity varia-
tions, whereas the FM function captures fast changing spatial
variability in the image intensity, and is given by the cosine of its
instantaneous phase function. This combined method is used to
differentiate structures based on the gradient of the pixel-based
frequency. Statistical structural information-based texture anal-
ysis techniques use texture features such as the average of standard
intensity deviation, intensity distribution, and entropy of a partic-
ular area (Kose et al., 2010).
Once texture information is extracted, statistical classiﬁers are
used to identify the region of interest, based on the texture pattern.
The classiﬁer can be deﬁned as a device or system with n inputs,
each of which is used to enter the information about one of n
Fig. 8. Gray scale retinal image (cropped) shows drusen in the macular area (left) and segmented image (texture based) for drusen detection output (right).
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siﬁed. An R-class classiﬁer will generate one of R symbols C1, C2,
.,CR as an output, and the user interprets this output as a decision
about the class of the processed object. The generated symbols CR
are the class identiﬁers (Sonka et al., 1999). The classiﬁers are of two
types: supervised classiﬁers and unsupervised classiﬁers or clus-
tering. A supervised classiﬁer uses training feature(s) (i.e., feature
vector) for a class/object to assign objects to one of a prespeciﬁed
set of classes based solely on the vector of measurements taken on
those objects (Hand, 2006). In contrast an unsupervised classiﬁer
measures or perceives similarities among the feature vectors (i.e.,
patterns) and ﬁnds the natural groupings or clusters in the multi-
dimesional data (Jain et al., 2000). Both supervised classiﬁers such
as the Artiﬁcial Neural Network (ANN) or Support Vector Machine
(SVM) or unsupervised techniques such as the Expectation Maxi-
mization (EM) or Fuzzy C-Means (FCM) Clustering are used to
identify the region of interest, e.g., drusen (Fig. 8) (Brandon and
Hoover, 2003),(Freund et al., 2009).
A neural network (NN) is a computational technique inspired by
biological neurons with the ability to adapt or learn, to generalize
and to cluster or organize data. It is structured as an input layer, a
hidden layer and an output layer: to accept input features, to train
the network based on the features, and to classify the features into a
certain number of classes. Back propagation or probabilistic
algorithm-based NN are used for classifying drusen and back-
ground after analyzing the features (Ripley, 1996).The SVM algo-
rithm is a classiﬁcation algorithmwhich transforms the input space
to a higher dimension feature space through a nonlinear mapping
function, and constructs a separating hyperplane with the
maximum distance from the closest value of the training set (He
et al., 2006).
The EM technique obtains a partition function for a class/cluster
based on the known patterns and assigns a cluster membership forTable 1
Summary of texture based drusen detection methods.
Method Image processing techniques
Brandon and Hoover (Brandon
and Hoover, 2003)
Mexican hat wavelet and Feed Forw
Kose et al. (Kose et al., 2010) Statistical texture properties and thr
based vessel detection
Parvathi and Devi (Parvathi and Devi, 2007) Log-Gabor ﬁlter and thresholding
Barriga et al. (Barriga et al., 2009) Mutiscale feature through AM-FM an
Agurto et al. (Agurto et al., 2011) Same as (Barriga et al., 2009)
Lee et al. (Lee et al., 2008) Multi-scale top hat ﬁlter and partitio
Freund et al. (Freund et al., 2009) Multi-scale analysis and Support Vec
Priya and Aruna (Priya and Aruna, 2011) Discrete wavelet transform and Proba new test sample by optimizing the closest similarity match with
highest probability (Lee et al., 2008). Fuzzy C-Means clustering
divides data elements into classes or clusters based on similarity
measures such as distance (e.g., Euclidian distance between feature
vectors), connectivity and intensity. Fuzzy C-Means clustering is
also referred to as soft clustering, which assigns data elements into
one or more classes with membership levels (Thaibaoui et al.,
2000), (Bhuiyan et al., 2007).
Table 1 summarizes the texture based methods and their
accuracy.
3.1.1.2. Thresholding-Based drusen segmentation. Thresholding is a
technique which converts an image into a binary image based on
intensity or frequency to obtain the region(s) of interest. A global
threshold value may be chosen automatically or on the basis of
clear points in the image histogram that would allow for efﬁcient
separation. More complex intensity criteria may be used to allocate
whether pixel values become white or black. For some images,
adaptive or local thresholding is useful where different thresholds
are applied to different sections of the image, e.g., when the image
has varying levels of background illumination (Patton et al., 2006).
In drusen detectionmethods (Smith et al., 2005), (Soliz et al., 2002),
the thresholding-based techniques mainly rely on pixel intensity,
derivative, histogram and local intensity probability to select the
threshold for drusen regions. Threshold-based drusen segmenta-
tion methods are summarized in Table 2.
In summary, Rapantzikos and Zervakis (Rapantzikos et al.,
2003), (Rapantzikos and Zervakis, 2001) showed excellent results
(up to 100% accuracy) on automated hard drusen detection
compared against manual segmentation by an expert grader.
However, they did not specify if the method can perform with
similar accuracy for soft drusen detection. Barkat and Madjarov
(Barakat and Madjarov, 2004) did not categorize drusen types toLevel of segmentation Accuracy (%)
ard Neural Network Drusen or non-drusen 87
Small or large drusen 71
esholding; edge Small area degeneration 84.06e92.64
Medium area degeneration 89.89e96.06
Large area degeneration 90.67e95.16
Drusen or non-drusen e
d ROI by Partial Least Squares Drusen and non drusen Up to 100
Soft and hard drusen 96
Drusen area 73
n function based clustering Drusen and non drusen 71.7e92.2
tor Machine Drusen absent or present e
abilistic Neural Network Dry and wet AMD 96
Table 2
Table: Summary of thresholding based drusen detection methods.
Method Image processing techniques Level of segmentation Accuracy (%)
Soliz et al. (Soliz et al., 2002) Median ﬁltering, Gaussian smoothing and
probability based thresholding
Drusen and non drusen 71
Drusen size 67
Smith et al.(Smith et al., 2003),
(Smith et al., 2005)
Otsu method for background selection and
intensity thresholding to segment drusen
Drusen detection sensitivity 42e86
Drusen detection speciﬁcity 5398
Drusen area detection 87.395.3
Rapantzikos and Zervakis (Rapantzikos
and Zervakis, 2001)
Homomorphic ﬁltering and histogram based
adaptive local thresholding
Drusen and non drusen Up to 100
Liang et al. (Liang et al., 2010) Edge based thresholding and morphological dilation Drusen detection sensitivity 75
Drusen detection speciﬁcity 75
Barakat and Madjarov (Barakat and
Madjarov, 2004)
Region of interest selection and intensity
thresholding
Drusen detection sensitivity 86
Drusen detection speciﬁcity 93
Morgan et al. (Morgan et al., 1994) Median ﬁltering, region subdivision and
intensity thresholding
Drusen area detection e
Y. Kanagasingam et al. / Progress in Retinal and Eye Research 38 (2014) 20e4230measure AMD severity. Morgan et al. (Morgan et al., 1994) showed
that a signiﬁcant number of drusen areas were miscalculated; a
major drawback of the system. Longitudinal changes were
measured in Soliz et al. (Soliz et al., 2002). However, the agreement
between the graders on different drusen sizes was only 67%.
3.1.1.3. Clustering-Based drusen segmentation. Cluster analysis or
clustering is the task of assigning a set of objects into groups so that
the objects in the same cluster are more similar to each other than
to those in other clusters. Clustering can be considered the most
important unsupervised learning problem; so, as with every other
problem of this kind, it deals with ﬁnding a structure in a collection
of unlabeled data. Our search for existing literature on AMD
detection based on clustering identiﬁed two papers, which are
summarized in Table 3.
Both methods focused on feature vector generation from in-
tensity distributions and spatial histograms, and did not consider
the validation for soft drusen detection or detection of other drusen
subtypes.
3.1.1.4. Edge and template matching. Edge detection deﬁnes the set
of pixels that form the border of a region that separates it from
neighboring regions. Edge detection is the approach used most
frequently for segmenting images based on abrupt (local) changes
in intensity. Most edge detection algorithms assess changes by
ﬁnding the magnitude of the gradient of the pixel intensity values.
In (Parvathi and Devi, 2007) edge-based soft drusen detection was
attempted, however, it is affected by the faint boundary properties
of soft drusen. The template matching method considers a tem-
plate of part of or the full image to match with to ﬁnd the region or
image of interest, and can be performed through two approaches:
feature-based and template-based matching (Gonzalez and
Woods, 2008). Although edge and template matching-based
methods work well for hard drusen segmentation, they fail to
detect soft drusen due to the fuzziness on the edges. Table 4
summarizes the existing methods on edge and template
matching-based drusen identiﬁcation.
Overall, the studies addressed AMD grading with drusen
absence or presence, drusen pixel identiﬁcation, and drusen size
detection for dry AMD identiﬁcation. The best methods thatTable 3
Summary of clustering based drusen detection methods.
Method Image processing techniques
Quellec et al. (Quellec et al., 2011) Factor analysis to generate feature space a
reference image distance based clustering
Hanaﬁ et al. (Hanaﬁ et al., 2010) Spatial histogram and similarity based claproduced high accuracy are summarized in Table 5. However, the
reported accuracies are not for the same datasets, and therefore
cannot be compared to each other.Table 6
3.1.2. Protocols for AMD grading using retinal color imaging
The international classiﬁcation of grading system divides the
macula area into three circles on the retinawhich are centered on the
fovea, of diameters corresponding to 1000 mm, 3000 mmand 6000 mm
(Bartlett and Eperjesi, 2007). Lesions are graded within each of the
central, inner or outer circles. The predominant drusen type is classed
as themost commontypeofdrusenpresentwithin theoutercircle. The
drusen are classiﬁed as hard drusen with size <63 mm, intermediate
soft drusen 63e125 mm, large semi-solid drusen 125e250 mm, 250e
500 mm and>500 mm. Other pathologies such as hyperpigmentation,
GA andneovascular AMDare graded as present or absent in the retinal
image. The AREDS study deﬁnes theAMDcategory as 1 to 4; normal to
severeAMDbasedon thedrusen,GA, andCNV. The studydeﬁnesAMD
category1 if there isnodrusenexistentordrusensize<63mmandtotal
area coveredbydrusen is< 125mm.AMDcategory2or intermediate is
deﬁnedasdrusensize63mmand<125mmanddrusenarea125mm
but GA absent. AMD category 3a is deﬁned as intermediate 63 mm
and <125 mm, drusen area > 360 mm diameter circle if soft distinct
drusenarepresentand3b if soft indistinctdrusenarepresent656mm
diameter circle. AMDcategory 4 (4a and4b) is advancedAMDwith the
presence of GA and CNV and visual acuity<20/32 due to AMD.
3.1.3. Existing AMD grading systems
Existing AMD grading systems based on color imaging (Klein
et al., 1991),(Gregor et al., 1977),(Smiddy and S, 1984),(Strahlman
et al., 1983) require a grader’s manual interaction, a very time
consuming and tedious process. Scholl et al. (Scholl et al, 2003)
proposed a semi-automated method for grading drusen and GA to
measure AMD severity. AMD severity was graded using a grid to
deﬁne macular subﬁelds and standard circles to deﬁne the size of
the lesions. Inter-observer variability was assessed by having three
retinal specialists evaluate the color slides and re-grade the same
set. The inter-observer agreement for hard drusen was 70e89%
(kappa ¼ 0.26e0.63) and intermediate soft drusen 76e94%
(kappa¼ 0.27e0.69). Agreement ranged between 87% and 100% for
larger drusen. Moderate to almost perfect agreement was reachedLevel of segmentation Accuracy (%)
nd Drusen and non drusen 85
ssiﬁcation AMD and non AMD image classiﬁcation 77
Table 4
Summary of edge and template matching based drusen detection methods.
Method Image processing techniques Level of segmentation Accuracy (%)
Mora et al. (Mora et al., 2011) Illumination correction, normalization and
Gaussian derivative
Drusen area detection 43
Drusen pixel detection sensitivity 68
Drusen pixel detection speciﬁcity 96
Remeseiro et al. (Remeseiro et al., 2009) Gaussian template matching and thresholding Drusen region identiﬁcation sensitivity 83
Drusen region identiﬁcation speciﬁcity 87
Table 5
Drusen detection approaches and best methods on reported accuracy.
Classiﬁcation of
drusen
References Accuracy
Accuracy Sensitivity Speciﬁcity
Absent or present (Agurto et al., 2011) 100% e e
Pixel level (Brandon and Hoover,
2003),
(Barakat and Madjarov,
2004)
87% 86% 93%
Drusen Region
or size
(Barriga et al., 2009) 96% e e
Hard or soft
drusen
e e e e
Distinct or In
distinct
e e e e
Dry or Wet AMD (Priya and Aruna, 2011) 96% e e
Y. Kanagasingam et al. / Progress in Retinal and Eye Research 38 (2014) 20e42 31for the presence of GA 88e98% (kappa ¼ 0.60e0.95) and substan-
tial to almost perfect agreement for the presence of CNV 84e100%
(kappa ¼ 0.62e1.00).
Although there has been a considerable amount of work done
on drusen detection, none of it addresses drusen classiﬁcation as
hard and soft drusen and distinct and indistinct drusen, which are
the key measures for early detection of AMD. The most chal-
lenging issues in drusen classiﬁcation are the varieties of size,
shape and intensity distribution for the drusen. In addition, it is
often difﬁcult to ﬁnd the boundaries of drusen, and they can be
difﬁcult to reliably identify, as they have a similar appearance to
other lesions, such as cotton wool spots. Some faint drusen can
also appear similar to normal features of the retina, such as the
background pattern caused by the normal choroidal vessels (Kose
et al., 2010).
Existing techniques for AMD severity grading using color fundus
imaging are mainly manual or semiautomatic. Due to the high
degree of graders’ involvement, the methods may also involve in-
accuracy and lack of repeatability (Niemeijer et al., 2007). Although
a number of methods have been proposed for drusen detection
(Rapantzikos et al., 2003),(Niemeijer et al., 2007),(Kose et al.,
2010),(Kösea et al., 2008) they mainly focus on detecting the
presence or absence of drusen. However, early and intermediate
AMD detection require drusen classiﬁcation (e.g., soft and hard
drusen, distinct or indistinct drusen) along with the macular regionTable 6
SD-OCT image analysis methods and reported accuracy.
Method Image processing techniques L
Chiu et al., 2012 Graph and dynamic programming S
D
Zhang et al., 2012 3D tube-like objects modeling for choroidal vessel and
Markov boundary model for retinal layer thickness
C
R
Liu et al., 2011 Multiscale texture and SVM A
a
Ghorbel et al., 2011 Active contours, Markov random ﬁelds and Kalman ﬁlter Lmapping. To the best of our knowledge, no automatic method has
been proposed to classify drusen as soft or hard, soft distinct or
indistinct and other drusen types. An automatic method should
provide higher accuracy and repeatability on grading the pathol-
ogies, which is the most important aspect for AMD screening.3.2. Fundus Autoﬂuorescence imaging
3.2.1. Fundus Autoﬂuorescence imaging for late “dry” AMD or GA
The literature search identiﬁed one automated segmentation
method for GA that also grades manually for dry AMD severity, as
proposed by Lee et al. (Lee et al., 2007). The manual method aims to
segment GA to determine the AMD severity. The method ﬁrst ap-
plies a non-linear adaptive smoothing operation to correct back-
ground illumination. A level set framework is then used to identify
the hypo-ﬂuorescent areas. Finally, an energy function combined
with morphological scale space analysis and a geometrical model-
based approach is performed to reﬁne the hypo-ﬂuorescent areas.
The clinically apparent areas of hypo-ﬂuorescence were drawn by
an expert grader and compared on a pixel-by-pixel basis to the
automated segmentation results, which achieved a sensitivity of
89% and speciﬁcity of 98%.3.3. Spectral domain Optical Coherence Tomography (SD-OCT)
In this review, we focus on different OCT image analysis tech-
niques for measuring AMD pathologies such as drusen, GA and
CNV.
3.3.1. SD-OCT for early or late “dry” AMD
Baumann et al. (Baumann et al., 2010) proposed a method for
segmentation and quantiﬁcation of drusen and GA from polariza-
tion sensitive OCT. The method ﬁrst locates the RPE based on
depolarizing characteristics (i.e., polarization scrambling). Drusen
are segmented by ﬁrst locating the actual position of the RPE by its
degree of polarization (DOPU). The line found by tissue-speciﬁc
contrast then acts as a backbone for the subsequent calculation of
the position where the RPE should be in a healthy eye. Finally,
drusen are segmented and quantiﬁed by calculating the difference
between the actual position and the normal ‘should be’ position
(Fig. 9).evel of segmentation Accuracy or agreement (%)
egment Retinal Boundaries Diff. GT and Grader 1 is 4.2  2.8 mm and GT and
Grader 2 is 3.2  2.6
rusen or GA Mean diff. 1.60  1.57%
horoidal vessel Corr. Coeff. 0.92
etinal layer thickness Boundary diff.  10 mm
MD pathologies (e.g., GA)
bsence or presence
Accuracy 94%
ayer segmentation Diff. between the method and grader
measurement is 4.75e12.5%.
Fig. 9. Example of drusen detection. Panel (a) presents an xez slice running through the pathology in SD-OCT volume. Footprint of drusen probability map in xey, are presented in b
and c, respectively.
Fig. 10. Segmentation results of 11 retinal surfaces (ten layers).
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in the depolarizing RPE pixels. This is achieved by simply summing
the number of polarized pixels for each A-line of the 3D PS-OCT
data set. The resulting thickness map of the depolarizing layer
then reveals the existence and absence of polarizing scrambling
tissue in an en face view. To prevent integrating choroidal pixels
into computing the thickness map of the depolarizing layer, only
depolarizing pixels located in a shallow band close to the photo-
receptor layer are used. The method did not provide any signiﬁcant
analysis for accuracymeasurement. The repeatabilitymeasurement
shows that the variation on drusen area and volumemeasurements
are 7.5e7.7% and 9.2% for GA.
3.3.1.1. Graph-Based drusen and GA segmentation. Chiu et al. (Chiu
et al., 2012) proposed a method for automatic segmentation of RPE
and drusen from SD-OCT images for the longitudinal study of
AMD. The method utilizes graph and dynamic programming to
segment three retinal boundaries in SD-OCT images with drusenand geographic atrophy. The graph search (GS) and graph cut (GC)
methods were synergistically combined to segment the exudates
associated derangements (SEAD) i.e., drusen and GA. The seg-
mentation problem can be formulated as an energy minimization
problem such that for a set of pixels P and a set of labels L, the goal
is to ﬁnd a labeling f: p/L that minimizes the energy function
En(f).
The graphs are constructed considering the superior surface,
inferior surface and region. The three subgraphs are then merged
together to form a single graph. The segmentation accuracy was
determined for layer thickness measurement and drusen or GA
volume measurement. The layer thickness (Fig. 10) accuracy was
measured by two certiﬁed graders which showed mean differences
of 4.2  2.8 mm and 3.2  2.6 mm for automatic versus manual
segmentation. The mean differences in the calculated total retina
and drusen volumes were 0.28  0.28% and 1.60  1.57% respec-
tively. The method showed very high efﬁciency: 1.7 s compared to
3.5 min manually.
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based on retinal layer thickness measurement and can be used to
ﬁnd abnormalities and/or for change detection due to drusen, GA
and CNV are as follows. A fully automated 3D SD-OCT segmentation
method for choroidal vessels, quantiﬁcation of choroidal vascula-
ture thickness and choriopillaris-equivalent thickness of macula is
presented in (Zhang et al., 2012). A graph-based multilayer seg-
mentation approach was utilized to segment intra-retinal surfaces.
Choroidal vessels were modeled as 3D tube-like objects in a
resampled sub-volume that yielded isometric (cubic) voxels. The
method shows good reproducibility in choriocapillaris-equivalent
(coefﬁcient of variation 8%) for normal subjects. Koozekanani
et al. (Koozekanani et al., 2001) proposed an automated algorithm
for retinal thickness measurement from OCT images using the
Markov boundary model. The detected boundaries from the auto-
mated method were compared with manually corrected bound-
aries, which showed that the method determined the thickness
with 10 mm difference (from the manual method) for 74% of images
(out of 1450 test images). For 98.4% of the images, the method
detected the thickness within 25 mm difference.
3.3.1.2. Texture-based GA segmentation. Liu et al. (Liu et al., 2011)
proposed an automated method to identify normal macula and
AMD from SD-OCT images using multi-scale texture and shape
features. A fovea-centerd cross-sectional slice for each of the SD-
OCT images was encoded using spatially-distributed multiscale
texture and shape features. Three ophthalmologists labeled each
fovea-centerd slice independently and the majority opinion for
each pathology was used as the baseline decision. Two-class sup-
port vector machine classiﬁers were trained to identify the pres-
ence of normal macula and each of the three pathologies (macular
hole, macular edema and AMD) separately. The method showed
good accuracy with an area under the receiver operating charac-
teristic (ROC) curve of 0.94.
3.3.1.3. Active contour-based drusen segmentation. Yi et al. (Yi et al.,
2009) performed a quantitative evaluation of drusen and associ-
ated structural changes in non-neovascular AMD using SD-OCT
images. They used a method (Mujat et al., 2005) which de-
termines the retinal nerve ﬁber layer (RNFL) thickness in OCT im-
ages based on anisotropic noise suppression and deformable
splines. A qualitative assessment was performed to report the
consistency of the method. However, no quantiﬁcation was per-
formed or correlation of the automated and manual grading was
shown.
Ghorbel et al. (Ghorbel et al., 2011) developed an automated
method for the segmentation of eight retinal layers in an SD-OCT
image. Fig. 7 shows the layers. The method is based on active
contours and Markov random ﬁelds. A Kalman ﬁlter is applied to
model the approximate parallelism between the photo receptor
segments. The method was validated by comparing against manual
segmentation performed by ﬁve different graders. Results showed
that the thickness measurement for the layers can vary between
the automatic and manual by up to 4.75e12.5%. However, they did
not use any images from AMD patients for the validation.
3.3.1.4. Gradient-Based GA segmentation. An automatedmethod for
intra-retinal boundary segmentation in SD-OCT was proposed for
fast and reliable quantiﬁcation GA (Yang et al., 2010). Local and
global gradient information is adopted simultaneously with a
shortest path search to optimally ﬁnd edges. The method was
validated against manually graded images for accuracy and repro-
ducibility, and showed high accuracy and reproducibility with
faster processing time. There may be potential for AMD severity
identiﬁcation.3.3.2. SD-OCT for exudative AMD
Choroidal vasculature in a standard clinical OCT scan is shown in
Fig. 9. In (Giovannini et al., 1999), the authors demonstrated the use
of OCT for displaying a neovascularization at the RPE. The ﬁndings
suggest that the surgical removal of early age-related CNV could be
performed in those cases where the OCT shows a neovascular
membrane on the RPE, as in idiopathic and inﬂammatory CNVs.
However, surgical removal of CNV is no longer state-of-the-art.
A review on recent developments in OCT for retinal imaging is
provided in (Drexler and Fujimoto, 2008), (Velthoven et al., 2007)
which discusses image acquisition and functionality with respect to
the strengths and weaknesses of different OCT technologies for
determining retinal structure and blood ﬂow capturing capabilities.
Algorithms and methodologies for retinal thickness measurement
can be found in (Koozekanani et al., 2001),(Song et al., 2012),(Tatrai
et al., 2011),(Ghorbel et al., 2011).
In summary, there continues to be much room for improvement
in imaging retinal layer segmentation, drusen and GA volume
measurement using OCT imaging. Accuracy measurements for the
drusen and macular layer segmentation algorithms for AMD are
provided in (Song et al., 2012),(Patel et al., 2009),(Schlanitz et al,
2011), (Loduca et al., 2010),(Ahlers et al., 2010). Manual or semi-
automated algorithms for drusen volume measurement for AMD
severity are described in (Khanifar et al., 2008),(Freeman et al.,
2010),(Schuman et al, 2009). Among the GA quantiﬁcation
methods, (Fleckenstein et al., 2010a,b),(Fleckenstein et al., 2008),
(Margins, 2009),(Lujan et al., 2009),(Yehoshua et al.,
2010a),(Yehoshua et al., 2010b) are manual or semi-automatic
and mainly focus on GA progression for AMD severity measure-
ment. Further, an automated analysis of OCT images can be found in
(Wilkins et al., 2012) which measures intra-retinal cystoids ﬂuid. A
comparison of SD-OCT devices and 3D drusen analysis software can
be obtained from (Kaiser, 2011). An SD-OCT 3D volumetric analysis
would also be applicable to SDDs as well as ordinary drusen, but
this has not yet been implemented.
3.4. Fluorescein angiogram or angiography
3.4.1. Fluorescein angiogram for “dry” AMD
A fewmethods have been developed for the automated analysis
of angiography images for detecting drusen and GA. Clinically, it has
been shown that soft drusen and macular subretinal new vessels
are associated in a statistically signiﬁcant manner (Thaibaoui et al.,
2000). Therefore, these methods aimed to detect drusen detection
from angiographic images, utilizing one imaging modality for both
“dry” and “wet” AMD pathology. Thaibaoui et al. (Thaibaoui et al.,
2000) developed a method from retinal angiographic images
which is based on image partition and fuzzy logic. At ﬁrst, the
method partitions the image into different classes with respect to a
probability density function of the input gray-levels. To improve the
homogeneity of the obtained classes, a local parametric gray-level
transformation of the classes is applied. This mainly transforms
the image into three classes, which are background, fuzzy region
and drusen. Fuzzy c-Means (FCM), a data clustering technique,
deﬁnes each data point as belonging to a cluster to some degree.
This is speciﬁed by a membership grade. Using fuzzy clustering
rules the regions are classiﬁed into background and drusen. The
method was not evaluated quantitatively or gave any comparison
with ground truth images.
Sbeh et al. (Sbeh et al., 2001) proposed amethod for longitudinal
change detection in ﬂuorescein angiography which is based on
mathematical morphology. Regional maxima components of the
image which correspond to the regions inside the drusen are ob-
tained. Shape, area and contrast of the detected regions are
analyzed to decide whether these regions are drusen. Following
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structure to observe changes in the longitudinal images. A quali-
tative analysis was provided on change detection, however no
quantitative result was provided nor any classiﬁcation results of
drusen given.
3.4.2. Fluorescein angiogram for “wet” AMD
A fully-automated approach for change detection of CNV has
been proposed in (Narasimha-Iyer et al., 2006). In this work, the
changes in CNV regions as well as the RPE hypertrophic regions
were detected and analyzed to study the progression of disease and
effect of treatment. Retinal features including the vasculature,
vessel branching/crossover locations, optic disk and location of the
fovea are ﬁrst segmented automatically. The images are then
registered to sub-pixel accuracy using a 12-dimensional mapping
that accounts for the unknown retinal curvature and camera pa-
rameters. Spatial variations in illumination are removed using a
surface ﬁtting algorithm that exploits the segmentations of the
various features. The changes are identiﬁed in the regions of in-
terest and a Bayesian classiﬁer is used to classify the changes into
clinically signiﬁcant classes. The automated change analysis algo-
rithms were found to have a success rate of 83% in detecting the
changes in CNV regions compared with manual segmentation.
3.5. Indocyanine Green (ICG) angiogram or angiography
3.5.1. ICG for “wet” AMD
A number of automatic methods (Miki et al., 2007), (Nishiyama
et al., 2001) have been reported on choroidal vascular change
detection. Miki et al. (Miki et al., 2007) measured the brightness of
diffuse ﬂuorescence at the macula from ICG angiograms at four and
16 s after dye ﬁlling. The ratio of the averaged brightness of the
macula to that of the disc (ch/d) was calculated for each angiogram.
Groups of people: healthy young volunteers, old AMD and old non-
AMD persons, were considered. There were signiﬁcant differences
in the ch/d ratios among the three groups four seconds after dye
ﬁlling, which showed that ICG may be helpful for objective evalu-
ation of the choroidal circulation in chorioretinal diseases. A
quantitative analysis of ICG angiographic images in central serous
chorioretinopathy (CSC) was presented in (Nishiyama et al., 2001).
Using a Topcon IMAGEbet(R) camera, the maximum diameter of
the choroidal veins and intensity of background ﬂuorescence in the
posterior fundus were measured with ICG video images. The study
showed that choroidal venous dilation and the residual background
ﬂuorescence in the posterior fundus might be positive indicators
reﬂecting the pathogenesis of CSC.
A study has been performed to identify the incidence of retinal
choroidal anastomoses in patients with occult CNV and focal hot
spots on ICG angiography to identify the clinical and angiographic
features (Slakter JS, 2000). The study identiﬁed speciﬁc clinical and
angiographic features that can aid in the diagnosis of these vascular
anomalies. A case report (Chang et al., 2004) has been published to
show correlation between ICG angiographic ﬁndings in patients
with exudative AMD with the histological localization of ICG to the
surgically excised CNV. The report showed that ICG angiography
allows diagnosis of CNV with high conﬁdence.
An examination of the in vitro interaction of human RPE cells
with ICG was performed and reported in (Chang et al., 2005). A
comparative study using ICG angiograms and intravenous sodium
ﬂuorescein angiography (IVFA) was reported in (Dzurinko et al.,
2004) which showed that ICG is better than IVFA. Simultaneous
visualization of an en face (coronal, C scan) OCT image and an ICG
angiogram, displayed side by side and superimposed, permits more
precise correlations between late ﬂuorescence accumulation and
structures deep in the retinal surface at the retinaechoroidinterface (Rosen et al., 2009). The paper also reported that SLO-
based ICG is particularly effective in ﬁnding small CNV lesions
masked by ﬂuorescein staining.3.6. Thermal/Infrared (IR) imaging
At present, IR image analysis for diagnosing AMD as neovascular
or exudative is mainly performed by graders (qualitative analysis).
Although a number of automatic methods have been proposed in
(Schardosim et al, 2011),(Kolar et al., 2008),(Devisetti et al., 2011;
Schardosim et al, 2011), they have not been tested in any clinical
applications.
3.6.1. IR for “dry” AMD
Existing IR-based “dry” AMD diagnosis techniques focus on GA
segmentation, change detection with image registration and mo-
tion detection. In (Schardosim et al, 2011), the motion detection
method was proposed to remove background noise and illumina-
tion from IR imaging. (Kolar et al., 2008) proposed a method for IR
and autoﬂuorescence image registration which is based on noise
suppression, edge detection, rigid or ﬂexible transformation and
interpolation. Devisetti et al. (Devisetti et al., 2011) developed a
method for GA segmentation using intensity distribution and
neural network-based GA pixel classiﬁcation.
Elsner et al. (Elsner et al., 1996) performed a comparative study
of IR and scanning laser ophthalmoscope for acquiring subretinal
structures. Their study showed that IR provides better visibility
than visible light. Kellner et al. (Kellner et al., 2010) showed that
near infrared (NIR) is equally capable of detecting RPE alteration as
FAF. They also showed that patterns from FAF and NIR indicate
different involvement of lipofuscin and melanin in the patho-
physiological process and provide further insight into the devel-
opment of AMD.
A qualitative assessment for neovascular AMD was provided for
near IR imaging in (Theelen et al., 2009) which was based on
graders’ observation. The paper concluded that NIR imaging in
neovascular AMD revealed characteristic alterations depending on
the type of CNV. These changes may reﬂect histological differences
of the lesions. Weinberger et al. (Weinberger et al., 2006) demon-
strated that NIR autoﬂuorescence is capable of detecting macul-
opathy as a single sensor. In (Forte et al., 2012), the authors showed
that near-infrared autoﬂuorescence might detect areas of RPE cell
loss at the GA margin earlier than fundus ﬂuorescence. Semoun
et al. (Semoun et al., 2009) analyzed an IR feature for CNV, awhitish
ring that is correlated to the edge of the lesion.3.7. Hyperspectral Retinal Imaging
3.7.1. Hyperspectral Retinal Imaging for “dry” AMD
Lee et al. (Lee et al., 2010) proposed a method for capturing
hyperspectral signatures of drusen and macular pigment. The
method adopted non-negative matrix factorization (NMF) for
ﬁnding low rank decomposition that captures the underlying
physiology of drusen and macular pigment. The feasibility of
hyperspectral mapping of macular pigment is also investigated in
(Fawzi et al., 2011). The study showed that snapshot hyperspectral
imaging in combination with advanced mathematical analysis
provides a simple, cost effective approach for macular pigment
mapping in vivo. Davis et al. (Davis et al., 2007) demonstrated that
hyperspectral images of macular tissue are spectrally different in
different forms of AMD.
Hyperspectral imaging-based techniques for monitoring oxygen
saturation in the optic nerve head and overlying vessels of monkey
eyes has been reported in (Khoobehi et al., 2004).
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based systems which cause severe motion artefacts and pixel
misregistration problems because of the constant micro movement
of the human eyes’ (Gao et al., 2012). To overcome this limitation, a
snapshot hyperspectral retinal camera which utilizes a computed
tomographic imaging spectrometer (CTIS) has recently been
developed for fundus imaging (Johnson et al., 2007). However, CTIS
is computationally very expensive and is limited by resolution
constraints. Considering this, a parallel acquisition hyperspectral
imager has been developed which uses an image mapping spec-
trometer (IMS) (Gao et al., 2012). Integrating an IMS with a tradi-
tional retinal camera, 48 simultaneous channel imaging of a human
retina was achieved, with measurement of reﬂectance and ab-
sorption spectra from vessels and macula. This system also allowed
measurement of the spectral reﬂectance of an optic disc druse,
which was previously unknown. In summary, this approach is still
in the early stage of development, without widespread clinical
application.
4. Comparative study of the AMD imaging modalities and
imaging techniques
Each imaging modality has strengths and weaknesses for diag-
nosing individual AMD pathology. Here, we focus speciﬁcally on the
strengths and weaknesses of an imaging sensor to capture AMD
pathology. Currently, color fundus imaging represents the gold
standard for looking at the retina for initial assessment of AMD. A
number of study protocols have been established for AMD severity
grading, which were discussed earlier. However, with the recent
advancement of new imaging modalities, more diagnostic infor-
mation can now be extracted from the retinal layers for AMD. For
example, SD-OCT can capture volumetric information on drusen
and other retinal ﬂuids. IR imaging has strengths for investigating
sub-retinal structures in the presence of hemorrhage or cataracts
that may be undetected in other in vivo studies.
A number of studies (Lujan et al., 2009),(Jain et al.,
2010),(Zweifel et al., 2010),(Rosenfeld et al., 2011),(Brar et al.,
2009) have been performed on showing the correlation for AMD
pathologies obtained from two different imaging modalities.
Among them Jain et al. (Jain et al., 2010) and Rosenfeld et al.
(Rosenfeld et al., 2011) showed a high correlation between color
fundus photographs (CFP) and SD-OCT images for drusen presence
and absence determination. There was also a trend towards higher
rates of drusen detection with SD-OCT in eyes with larger drusen
and hyper pigmentation, with CFP trending towards greater
detection of smaller drusen.
4.1. Autoﬂuorescence and IR vs. angiography/color fundus imaging
Metabolic changes at the level of the photoreceptor/RPE are
complex andmay not be able to be visualized using fundus cameras
or other routine imaging techniques such as FA. Kellner et al.
(Kellner et al., 2010) showed that NIR is equally capable of detecting
RPE alteration as FAF. In (Forte et al., 2012), the authors showed that
NIR autoﬂuorescence might detect areas of RPE cell loss at the GA
margin earlier than FAF.
4.2. SD-OCT vs. color fundus imaging
SD-OCT is better than other imaging modalities at capturing
information non-invasively and for the quantitative assessment of
all forms of AMD (Yehoshua et al., 2010b). SD-OCT enables the
physicians to obtain reproducible and quantitative data to follow
the disease as it progresses from drusen to both GA and CNV. SD-
OCT allows the accurate measurement of drusen area, which wasa drawback for AREDS (size was measured to avoid difﬁculty in the
measurement (Yi et al., 2009)). However, SD-OCTonly shows better
performance for larger drusen i.e., for advanced AMD rather than
for the smaller drusen: precisely identifying the borders of drusen
is still a challenge (Jain et al., 2010). In contrast, CFP provides better
information for smaller drusen. Therefore, CFP is useful for
screening and early detection of AMD.
4.3. OCT/TD-OCT vs. SD-OCT
Non-exudative or “dry” AMD does not directly beneﬁt from OCT
in visualization. SD-OCT is better than OCT in determining details of
the pathologies and faster (400 vs. 20,000e40,000 A scans) for
capturing the data.
A comparative study between OCT/TD-CT and SD-OCT was
performed in (Domalpally et al., 2010),(Gupta et al., 2008),(Kiernan
et al., 2010). SD-OCT tends to derive increased retinal thickness and
decreased nerve ﬁber layer thickness measurements. This is likely
because of the increased depth resolution and greater volume of
data acquired with each scan. SD-OCT has advantages over TD-OCT
by providing better identiﬁcation of normal and pathologic struc-
ture in patients with poor media clarity. SD-OCT is also faster than
TD-OCT and better for noise handling.
4.4. SD-OCT vs. FAF
The size and shape of GA areas measured by SD-OCT and FAF
correlate well (Lujan et al., 2009),(Brar et al., 2009),(Bearelly et al.,
2009),(Sohrab et al., 2011). The strength of SD-OCT is that it pro-
vides important cross-sectional anatomical structures. In non-
neovascular AMD with GA, SD-OCT provides adequate resolution
for quantifying the loss of the photoreceptor (PR) layer. It may also
serve as a means of tracking disease progression.
4.5. Fluorescein Angiography vs. ICG angiography
ICG angiography has several advantages over FA in imaging
choroidal vasculature. Because of the poor transmission of ﬂuo-
rescence through ocular media opaciﬁcation, fundus pigmentation
and pathologic manifestations (e.g., lipid exudation), FA has limi-
tations in imaging choroidal circulation. Recently, ICG angiography
has shown that it is more useful than FA for detecting CNV in
neovascular AMD (Klais and Yannuzzi, 2004).
A synopsis for the various imaging modalities for automatic
analysis of AMD pathologies:
 SD-OCT is better for the measurement of size, area or volume of
drusen and other pathological objects in the retina.
 CFP has strength over SD-OCT in the accurate measurement of
smaller drusen. SD-OCT has better accuracy for larger drusen
and hyper pigmentation measurement.
 GA using FAF is sufﬁcient, however SD-OCT is better as it pro-
vides cross-sectional anatomical information.
 IR imaging is less harmful for the eye, hence increased illumi-
nation can be used that may be valuable in increasing image
quality.
 ICG angiography is useful for detecting CNV in neovascular
AMD.
5. Telemedicine for AMD screening and computer-aided
automation
Telemedicine models in ophthalmology utilize telecommuni-
cation andinformation technologies in order to providespecialist
eye care at a distance. Telemedicine-related eye care and screening
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lead to overall savings in healthcare costs. It can enable early
detection of sight-threatening eye diseases (Yogesan et al., 2006),
(Yogesan et al., 2010) through facilitating mass screening. Several
feasibility studies demonstrate the enormous usefulness of the
technology (Abràmoff and Suttorp-Schulten, 2005),(Joshi and
Sivaswamy, 2011),(Lorenz et al., 2009),(Liesenfeld et al.,
2000),(Murakami et al., 2009).
Telemedicine has proven particularly effective for diabetic reti-
nopathy screening. In the US andworldwide, models of diabetic care
in both large and small scale health care systems, have emphasized
diabetic screening clinics. Often using telemedicine and systematic
organizational procedures, these models have substantially
improved the ocular screening rate for retinopathy to approximately
57% in the commercial insurance sector, 66% in the Medicare popu-
lation, 53% for theMedicaid insured, and90% in integratedhealthcare
organizations such as the US Department of Veterans Affairs (Hedis,
2012), (Taylor et al., 2007), (Yogesan et al., 2012), (Li et al., 2011).
However, such screening programs for AMD are virtually
nonexistent, especially in light of its high disease prevalence and
social impact. Additional studies in this area of telemedicine,
deﬁning optimal conditions for AMD screening and referral, are
needed. In theory, telemedicine-based screening of individuals over
55 years old could detect the presence of AMD at a level requiring
referral to an ophthalmologist for further examination. However,
from the viewpoint of a healthcare system or model, there is a need
to minimize unnecessary referrals and increase the cost-
effectiveness of screening by referring only those with a level of
pathology for which intervention is currently possible. Telemedi-
cine and ancillary tools could conceivably also be used for remote
monitoring of patients with “wet” AMD post-treatment, a model
that has the potential to result in close monitoring of anatomic and
visual outcomes, combined with a reduction in patient travel.
Our literature search found only a few telemedicine-based AMD
screening programs. Pirbhai and Sheidow (Pirbhai and Sheidow,
2004) showed that telemedicine can be used to diagnose AMD
patients with high conﬁdence using non-stereo CFP. The automatic
system could achieve 89.2% sensitivity and 99.1% speciﬁcity for
detecting CNV. For the presence of RPE GA the speciﬁcities were up
to 86.8%. Very few treatable lesions were missed in AMD patients.
Ulrich et al. (Ulrich et al., 2009) conducted a telemedicine trial
from Nepal to the USA to provide AMD and diabetic retinopathy-
related consultations using fundus images. They deﬁned early
AMD as any type of non-exudative changes with a visual acuity
>20/200 and advanced AMD as any exudative changes or advanced
atrophic disease with a visual acuity (  20/200).
Zimmer et al., 2005 (Zimmer-Galler and Zeimer, 2005) explored
the use of a telemedicine-based semi-automated screening system,
designed to be in primary care physician’s ofﬁces, to identify high
and low-risk AMD patients (21 patients). They concluded that it is
possible to identify low risk lesions with good agreement and high-
risk lesions with excellent agreement compared to gold standard
evaluation of stereoscopic ﬁlm photographs.
Telemedicine based screening could conceivably be combined
with automated image analysis and grading to facilitate early
detection and referral by trained screeners. The addition of auto-
mated decision support could provide guidance to remote primary
care providers and nurses in order to locally manage patients with
eye diseases. Telemedicine technology combined with computer-
aided grading may be a more effective care model for developing
countries which have large affected populations and fewer oph-
thalmologists (Eccles, 2012). Validated tele-screening could allow
prioritization of patients based on clinical urgency, with apparent
“wet” AMD lesions being detected and treated sooner than patients
whose conditions are rated as “dry” AMD.OCT imaging is an ideal imaging modality for telemedicine-
based screening and management (e.g., to determine whether
further VEGF inhibitor injection is indicated) of AMD and other
retinal diseases. It is non-invasive and relatively straightforward for
a technician to use. However, the cost of the device and its relative
immobility currently discourages it from being used outside eye
clinics,and therefore as a component of a tele-AMD program. Low
cost (probably< $10,000) portable OCT imaging devices are needed
for use in telemedicine consultations. Another issue that arises with
OCT imaging is that the 3D scans produce large image ﬁles that
need sufﬁciently high bandwidth for transmission. Ongoing
research opportunities exist to explore how to efﬁciently compress
OCT scans without loss of diagnostic information. A lossless
compression algorithm for maintaining detailed information in
OCT scans is a key part of the telemedicine platform to enable real-
time diagnosis.
Electronic medical records (EMR) are becoming an integral part
of any medical or eye clinic seeking to effectively manage patient
care and improve clinical outcomes. Integrating health information
digitally, both data and images, reinforces the importance of ocular
imaging devices that may be directly connected to the EMR.
Collected digital information includes color fundus and OCT images
that may be archived with other clinical data. The EMR data and
images could be located in the data cloud or at a remote server. In
principle, ophthalmologists could access the image-rich EMR
locally or remotely to provide diagnostic advice and triage. When
storing fundus images and clinical data in the cloud, appropriate
encryption must be implemented to protect sensitive patient in-
formation, and this issue has somewhat limited cloud andwireless-
based medical communication in large organizations.
Presently, it is not uncommon for image analysis and data pro-
cessing to be performed in the data cloud, to avoid installing in-
dividual software programs on each computer. The images are
transferred to the cloud for analysis. Other implications of such a
model of care include the need for high bandwidth, as image
transfer and processing must be rapid if one wishes to provide real-
time disease grading and clinical decision support to screeners. An
advantage of such a cloud-based data model is the relative ease
with which developers may upgrade and maintain the software
remotely.
As ophthalmology is strongly an image-based medical speci-
ality, the store-and-forward modality is widely used in tele-
ophthalmology systems rather than real-time video conferencing.
High resolution retinal images could be stored and transmitted to a
remote site for reading by an ophthalmologist. This could remove
the immediate need for high bandwidth communication lines and
real-time consultations. However, in some countries (e.g.,
Australia), only real-time video consultations are approved by
Medicare for reimbursement. Therefore, unless laws are changed, a
hybrid systemwith both store-and-forward and video conferencing
would be necessary. However, it is cumbersome and relatively
expensive to transmit high-resolution color images in real time and
also conduct simultaneous video conferencing. One solution is to
transmit high-resolution color images in advance through a store-
and-forward technique. After analyzing the retinal images and
other data, the ophthalmologist could speak to the patient and
referring health care provider using video conferencing.
Conventional video conferencing technology, while relatively
widespread in industrialized countries, carries its limitations of
image resolution and bandwidth as a relative barrier between pa-
tient and ophthalmologist. The traditional video conferencing
system has one camera and a screen, and does not give the
impression carried by a face-to-face consultation. In the future,
more advanced models of video conferencing, using multiple
cameras and screens, conceivably with the implementation of
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mologist the impression of a more “real” contact, and an enhanced
telemedicine experience. In principle, there is no reason that retinal
images could not be viewed in a three dimensional format as well.
The development of standards for tele-AMD consultation are
important to provide uniform care for patients and allow compa-
rability of studies. Additional telemedicine studies are required for
the screening and remote management of AMD in order to develop
appropriate tele-AMD standards. The standards could fall into two
domains:
1) Technical
a. Data Capture (imaging devices and other diagnostic devices)
b. Storage (image and data compression)
c. Transmission (protocols, smart phones)
d. Processing (image processing and automation)
e. Quality (display e screen properties)
2) Health application
a. Assessment (clinical guidelines, screening consultations)
b. Diagnosis (reporting guidelines, remote testing and imaging,
decision making and expert consultation)
c. Treatment (formulation of care plans, prescribing and
medication)
d. Management (execution and modiﬁcation of care plans)
e. Monitoring (recording frommedical devices, analysis of data,
images etc.).
In summary, while the AREDS clinical trials validated the
concept that retinal images and their grading extend direct patient
examination, widespread telemedicine screening for AMD awaits
advances in medical informatics, image processing, and health
applications (Ferris et al., 2005), (Davis et al., 2005).6. Clinical trials for identiﬁcation and follow-up of AMD
patients
A number of studies have been performed on AMD progression
and the effect of vitamin supplementation as well as intravitreal
drug injection (Klein et al., 2002; Bartlett and Eperjesi, 2007; Age-
Related-Eye-Disease-Study-Research-Group, 1999). The Beaver
Dam Eye Study showed an overall 10 year incidence rate of 12.1% for
early AMD (deﬁned as drusen and retinal pigment epithelial
changes) and 2.1% for late AMD (deﬁned as exudative AMD or
central GA) (Klein et al., 1992).
The revolution in care of neovascular AMD, however, is the
result of clinical trials which demonstrated statistically signiﬁcant
improvement in both visual acuity and anatomical results
(Rosenfeld et al., 2006). This study evaluated Ranibizumab e a re-
combinant, monoclonal antibody, for the treatment of neovascular
CNV. Results showed that intravitreal administration of ranibizu-
mab for two years prevented vision loss and improved mean visual
acuity, with a low rate of adverse effects, in patients with choroidal
neovascular (CNV) AMD. In another study (Keane et al., 2008), the
effects of ranibizumab on retinal morphology in patients with
neovascular AMD was demonstrated using OCT. OCT images were
analyzed using custom software that allows precise positioning of
pre-speciﬁed boundaries on anatomical data. Changes in the
thickness/volume of the retina, sub-retinal ﬂuid (SRF), sub-retinal
tissue (SRT), and PEDs were calculated at week 1 and at months
1, 3, 6, and 9 after treatment. The ﬁndings indicated that neuro-
sensory retinal edema and SRF showed early reductions after the
initiation of Ranibizumab therapy, and the effect on the retina was
attenuated over time, suggesting possible tachyphylaxis. PED vol-
ume showed a slower but progressive reduction.An earlier study has also been performed to determine whether
intravitreal bevacizumab (Avastin, a monoclonal antibody from
which ranibizumab is derived) could improve OCT results and the
visual acuity outcome in a patientwith neovascular AMD. (Rosenfeld
et al., 2005). Within one week, OCT results demonstrated the reso-
lution of SRF, resulting in a normal appearing macular contour, and
themacular appearance andvisual acuitywasmaintained for at least
four weeks. Subsequently, a number of studies were performed on
safety, biological effect, and a possible mechanism of action of
intravitreal bevacizumab in patients with neovascular AMD (Avery
et al., 2006),(Bashshur et al., 2006). These studies reported that the
intravitreal injection has no signiﬁcant ocular or systemic side ef-
fects. One week after injection, most patients had a reduction of
baseline macular thickness, and after four weeks 30 of 81 eyes
demonstrated complete resolution of retinal edema, SRF, andPED. Of
the 51 eyes with an eight-week follow up, 25 had complete resolu-
tion of retinal thickness, SRF and PED. A number of comparative
studies have been performed to evaluate the relative efﬁcacy and
safety of treatment of neovascular AMDwith ranibizumab (Lucentis)
and bevacizumab (Avastin) on a ﬁxed and variable schedule (Group
et al., 2011), (Catt-Research-Group et al., 2011), (Rosenfeld, 2006).
These studies utilized ranibizumab as the trial agent and demon-
strated that it is an effective treatment for neovascular AMD.. These
and other studies demonstrate that while the risk of injection is low,
ocular complications such as endophthalmitis, vitreous hemorrhage,
and retinal detachment are possible, as are slightly increased rates of
subsequent myocardial infarction and cerebrovascular accidents,
compared to those not undergoing injection. Following the encour-
aging clinical trial results with ranibizamab, several investigators
began evaluating intravitreal bevacizumab for the treatment of CNV.
Given its molecular similarity to ranibizamab, its low cost ($50
compared to $1,950), and its availability, the interest in Avastin has
been considerable (Catt-Research-Group et al., 2011). However,
cautionary reports of widespread endophthalmitis resulting from
inappropriate pharmacy preparation have made adherence to com-
pounding standards mandatory (Goldberg et al., 2012)
There is currently no approved treatment for the “dry” type of
AMD. However, the numerous AREDS studies (AREDS, 2001),
(AREDS, 2007) have early or late “dry” AMD. However, the AREDS
has shown that in patients with intermediate and advanced AMD
there is a statistically signiﬁcant reduction in the risk of progression
to advanced AMD with antioxidant and zinc supplementation, and
this effect persists for 10 years in approximately 25% of appropri-
ately treated individuals (Chew et al., 2013).Clinical innovation in
the area of “dry” AMD is ongoing. A selected investigational drug,
ACU-4429 (Acucela, Bothell, WA) has been used for investigating
the downregulation of photoreceptor activity. The ongoing phase 1
study has thus far shown that the drug is safe and well tolerated in
healthy volunteers. A clinical trial looking at the preservation of
photoreceptors and the RPE was followed by a therapeutic strategy
used for the treatment of Alzheimer’s disease (Rosenfeld, 2009). An
antibody against amyloid b was used in a phase 1 study as an
intravenous treatment for GA in AMD patients. This antibody,
known as RN6G (Pﬁzer, New York, NY), was shown to decrease the
amount of amyloid b in the eye from a mouse model of AMD when
given as a systemic therapy (Ding et al., 2008). Other studies are
evaluating newer treatments to prevent the progression from
nonexudative to exudative AMD.
7. Limitation of current imaging modalities and image
analysis techniques
The following limitations were highlighted within the current
systems by the symposium on advances in optical imaging and
biomedical science (2009):
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 need for eye motion correction
 need for improved estimates of light safety for the eye
 integration of imaging technologies in the next generation of
super cameras
 improved, less noisy SD-OCT imaging.
The development of SD-OCT alone has increased speed by
roughly two-fold and frequency-swept OCT provides additional
gains. These increases notwithstanding, image acquisition remains
a fundamental limitation to the scientiﬁc and clinical value of the
new imaging technologies. One reason that speed is so important in
ocular imaging is because the eye is always in motion due to
naturally occurring eye movements. The problem can be exacer-
bated in patient populations that have inferior ﬁxation ability. The
shorter the image acquisition time, the less image blur and
distortion due to eye motion. A complementary approach to
increasing speed is to correct for eye motion. Eye motion correction
can be achieved either through active tracking and image stabili-
zation during image acquisition, or through clever post-processing
to remove eye movement artifacts.
Given the need for speed outlined above, parallel development
of automated analysis software is also required. This includes
software for eye motion correction, visualization, and feature
analysis such as the development of improved segmentation al-
gorithms for identifying speciﬁc retinal layers (particularly from
OCT images) that are disrupted in retinal disease. Software that
allows repeatability and reproducibility from the same patient
would facilitate longitudinal studies of disease progression and/or
efﬁcacy of therapy.
Another need for improvement is the estimation of light safety.
The more light one can put onto the retina, the faster an image can
be acquired and the better the quality of the image. However, there
are very important safety limits for light intensity. Recent evidence
suggests that the light safety standards do not adequately protect
the eye under some conditions.
8. Conclusions and future directions
In this review, we described current ocular imaging modalities
and their strengths and weaknesses for extracting different path-
ological information relevant to the clinical care of AMD. We also
discussed existing methods for AMD screening through the use of
automated or semi-automated measurement of pathologies. Our
study found that the majority of automated or semi-automated
methods focus predominantly on grading drusen using different
imaging techniques, as drusen are among the ﬁrst clinical signs of
AMD. Multi-modal imaging studies and their strengths and weak-
nesses were also discussed. Use of these tools have the potential to
increase the sensitivity and speciﬁcity of screening in determining
the severity of AMD. We also outlined the potential for future
retinal imaging systems and the next generation of AMD grading
tools for monitoring disease progression.
The potential for widespread AMD screening and diagnosis
would likely beneﬁt with a focus on research in automated grading
andmass screening using a telemedicine platform. Such a validated
tool would be highly effective for the early detection of AMD by
nurses or trained screeners, as it is for diabetic retinopathy.
Currently, the sole established treatment option for “dry” AMD is to
detect the disease at a stage where AREDS formulationmay provide
a measure of treatment to prevent further degeneration and vision
loss. Therefore an important interventional focus should be on the
logistics of large-scale screening for AMD detection, targeting both
urban and rural populations. Although there are few studies on
tele-AMD, the AREDS studies did establish the usefulness ofstandardized images in grading disease and the effectiveness of
AREDS formulation in treatment of selected individuals. Additional
studies are needed to demonstrate the utility of telemedicine for
the widespread screening and management of AMD. OCT imaging
could be an excellent ancillary tool for tele-AMD applications, but
their role in remote and rural clinics remains to be deﬁned.
To datewe have not identiﬁed publications related to automated
analysis of drusen classiﬁcation (hard and soft, distinct and indis-
tinct), GA and CNV identiﬁcation that can be key measurements for
AMD severity identiﬁcation. Automated clinical decision support
for AMD with a telemedicine platform may be a potential option to
achieve this goal. A highly accurate AMD pathology classiﬁcation
system, similar to what was used in the AREDS-related publica-
tions, is needed in order to develop a telemedicine based AMD
screening system integrated with automated clinical decision
support. This could guide screeners to refer patients in a timely
manner.
The current clinical standard of care, SD-OCT, has been shown to
be the best analytical tool to non-invasively extract pathological
size and volumetric information from retinal imaging, as well as to
provide quantitative measurement of macular changes over time.
However, it has known limitationsin detecting certain pathologic
changes, while at the same time CFP has shown strength in the
extraction of small drusen information but lacks large drusen
boundary accuracy. One could consider using a multi-modality
image fusion approach, which could use CFP images and SD-OCT
images, with the application of novel feature extraction and
feature fusion techniques. Since OCT is currently not practical for
screening due to its expense, an OCT/CFP fusion approach may not
be the best current option for early detection, but such a tool may
be viable in the future for a screening role. Thus, a complement of
such sensors may provide a better method for AMD severity
identiﬁcation, monitoring of AMD progression, and clinical
intervention.
The Optical Imaging and Biomedical Science Conference 2009
recommended a number of areas for improvement and future
works that are summarized as follows:
 The value of integrating imaging technologies in the next gen-
eration of super cameras by combining OCT and adaptive optics,
OCT and multiphoton microscopy, or adaptive optics and
ﬂuorescence.
 The promise of functional imaging: There is increasing excite-
ment about combining new functional imaging with structural
imaging. For example, we can currently monitor blood ﬂowwith
Doppler OCT and analyze the response of single photoreceptors
to light with interferometric methods. These methods can
detect subtle changes in the refractive index inside single cells.
 For clinical applications, we need to develop non-invasive ways
to assess function. These methods include measuring the
intrinsic scattering changes of retinal cells in response to stim-
ulation, localized sensitivity thresholds (microperimetry), and
the combination of electroretinography with high resolution
imaging.
In addition, the following areas can be expanded for accurate
and efﬁcient AMD screening.
8.1. Expert system for AMD screening
A clinical decision support system for AMD based on telemed-
icine, automated image analysis, artiﬁcial intelligence and machine
learning techniques (e.g., ANN or SVM) using multiple imaging
modalities could be a huge advance in disease management. First,
the system could be trained for the automated identiﬁcation of
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to grade disease severity. In the analysis phase, such a tool utilizing
imaging and biomarker sensitivity might be used in conjunction
with ophthalmic expertise to further reﬁne the staging and treat-
ment of disease, further exploiting imaging and biomarkers.
8.2. 3D imaging
Besides OCT, 3D imaging of color and other 2D imaging mo-
dalities can provide better information on the retinal surface, and
consequently improved pathology detection. 3D visualization of
the retina could assist a remote ophthalmologist in viewing the
retina with a similar clinical conﬁdence as an in-person
examination.
8.3. Portable camera with multimodal imaging options and
computer-aided decision support
Portable, low-cost non-mydriatic fundus cameras capable of
producing diagnostic quality retinal images would be a great boost
in achieving the goal of community screening by trained nurses or
primary care providers. Fundus cameras with fully automated
focusing and image capturing would be invaluable to imagers.
Finally, while presently only a theoretical possibility, a portable
fundus camera with in-built image analysis and automated clinical
decision support for diseases such as diabetic retinopathy, AMD
and glaucomawould be a goal worth striving for in detecting major
causes of treatable blindness.
8.4. Imaging kiosk of the future
Asmentioned above, it is possible to envision a single system for
the screening of diabetic retinopathy, glaucoma and AMD. It could
be designed to be fully automated, from taking a photograph to
automated image analysis. Many of the engineering and software
components of such a “holy-grail” ocular health project either
already exist today or are in their infancy. Such a goal is worth
pursuing for its immense public health value, and these kiosks
could be located at optometry practices, pharmacies and primary
care clinics.
In the clinical setting of an eye clinic, an automated system that
facilitates grading of age-related macular change would probably
not add signiﬁcantly to the patient outcome or evaluation. How-
ever, as newmedications, genomicmedicine innovations, and other
interventions become available to identify and treat those at
greatest risk of AMD, the ability to detect early stage AMD will
allow improved clinical outcomes for this disease. A ﬁnal thought
for a person at risk for AMD, therefore, is that their visual prognosis
may rest on making an investment in an automated system that
useslow cost OCT and/or fundus imaging, allowing population-
based screening to identify such individuals at an early stage.
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